Your browser doesn't support javascript.
loading
Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis.
O'Mahony, Constantinos; Akhtar, Mohammed Majid; Anastasiou, Zacharias; Guttmann, Oliver P; Vriesendorp, Pieter A; Michels, Michelle; Magrì, Damiano; Autore, Camillo; Fernández, Adrián; Ochoa, Juan Pablo; Leong, Kevin M W; Varnava, Amanda M; Monserrat, Lorenzo; Anastasakis, Aristides; Garcia-Pavia, Pablo; Rapezzi, Claudio; Biagini, Elena; Gimeno, Juan Ramon; Limongelli, Giuseppe; Omar, Rumana Z; Elliott, Perry M.
  • O'Mahony C; The Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, London, UK.
  • Akhtar MM; UCL Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, London, UK.
  • Anastasiou Z; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-HEART).
  • Guttmann OP; The Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, London, UK.
  • Vriesendorp PA; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-HEART).
  • Michels M; UCL Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, London, UK.
  • Magrì D; Department of Statistical Science, University College London, London, UK.
  • Autore C; The Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, London, UK.
  • Fernández A; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-HEART).
  • Ochoa JP; UCL Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, London, UK.
  • Leong KMW; Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Varnava AM; Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Monserrat L; Clinical and Molecular Medicine, University 'La Sapienza', Rome, Italy.
  • Anastasakis A; Clinical and Molecular Medicine, University 'La Sapienza', Rome, Italy.
  • Garcia-Pavia P; Department of Cardiology, Favaloro Foundation University Hospital, Institute of Cardiology and Cardiovascular Surgery, Buenos Aires, Argentina.
  • Rapezzi C; Department of Cardiology, Favaloro Foundation University Hospital, Institute of Cardiology and Cardiovascular Surgery, Buenos Aires, Argentina.
  • Biagini E; GRINCAR (Cardiovascular Research Group), University of A Coruña, A Coruña, Spain.
  • Gimeno JR; Scientific Department, Health In Code, A Coruña, Spain.
  • Limongelli G; Imperial College Healthcare NHS Trust, London, UK.
  • Omar RZ; Imperial College Healthcare NHS Trust, London, UK.
  • Elliott PM; Scientific Department, Health In Code, A Coruña, Spain.
Heart ; 105(8): 623-631, 2019 04.
Article en En | MEDLINE | ID: mdl-30366935
ABSTRACT

OBJECTIVE:

In 2014, the European Society of Cardiology (ESC) recommended the use of a novel risk prediction model (HCM Risk-SCD) to guide use of implantable cardioverter defibrillators (ICD) for the primary prevention of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). We sought to determine the performance of HCM Risk-SCD by conducting a systematic review and meta-analysis of articles reporting on the prevalence of SCD within 5 years of evaluation in low, intermediate and high-risk patients as defined by the 2014 guidelines (predicted risk <4%, 4%-<6% and ≥6%, respectively).

METHODS:

The protocol was registered with PROSPERO (registration number CRD42017064203). MEDLINE and manual searches for papers published from October 2014 to December 2017 were performed. Longitudinal, observational cohorts of unselected adult patients, without history of cardiac arrest were considered. The original HCM Risk-SCD development study was included a priori. Data were pooled using a random effects model.

RESULTS:

Six (0.9%) out of 653 independent publications identified by the initial search were included. The calculated 5-year risk of SCD was reported in 7291 individuals (70% low, 15% intermediate; 15% high risk) with 184 (2.5%) SCD endpoints within 5 years of baseline evaluation. Most SCD endpoints (68%) occurred in patients with an estimated 5-year risk of ≥4% who formed 30% of the total study cohort. Using the random effects method, the pooled prevalence of SCD endpoints was 1.01% (95% CI 0.52 to 1.61) in low-risk patients, 2.43% (95% CI 1.23 to 3.92) in intermediate and 8.4% (95% CI 6.68 to 10.25) in high-risk patients.

CONCLUSIONS:

This meta-analysis demonstrates that HCM Risk-SCD provides accurate risk estimations that can be used to guide ICD therapy in accordance with the 2014 ESC guidelines. REGISTRATION NUMBER PROSPERO CRD42017064203;Pre-results.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Cardiomiopatía Hipertrófica / Muerte Súbita Cardíaca / Medición de Riesgo Tipo de estudio: Diagnostic_studies / Etiology_studies / Evaluation_studies / Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans País como asunto: Europa Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Cardiomiopatía Hipertrófica / Muerte Súbita Cardíaca / Medición de Riesgo Tipo de estudio: Diagnostic_studies / Etiology_studies / Evaluation_studies / Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans País como asunto: Europa Idioma: En Año: 2019 Tipo del documento: Article